GlassScriptPhysician profile
Sin Kei Yeung
NPI 1669704607
$9,854.45
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,790 · 2020: $1,585 · 2021: $1,914 · 2022: $2,088 · 2023: $2,138 · 2024: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,476.77 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,344.08 | 2020-2024 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $922.19 | 2019-2024 | Mounjaro, Jardiance, Baqsimi |
| Glaxosmithkline, LLC. | $816.29 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $703.77 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $637.79 | 2019-2023 | Jardiance |
| Astellas Pharma US INC | $630.09 | 2019-2024 | Myrbetriq, Veozah |
| Pfizer INC. | $490.66 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $479.88 | 2019-2024 | Farxiga, Breztri, Fasenra |
| Merck Sharp & Dohme LLC | $477.53 | 2019-2023 | Belsomra, Steglatro, Pifeltro |
| Amgen INC. | $414.28 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $336.29 | 2021-2023 | |
| Allergan, INC. | $274.35 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.75 | 2019-2023 | Xifaxan |
| Amarin Pharma, INC. | $213.13 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $208.73 | 2021-2023 | Rexulti |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sin Kei Yeung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.